Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings

Journal of Infectious Diseases

Volumn 207, Issue SUPPL.2, 2013, Pages

  Hosseinipour, Mina C ^a,b   Gupta, Ravindra K ^c   Van Zyl, Gert ^d   Eron, Joseph J ^b   Nachega, Jean B ^e,f,g  

^a UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e UNIVERSITY OF STELLENBOSCH   (South Africa)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

antiretroviral drug resistance; resource limited settings; second line therapy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; INDINAVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; DISEASE SURVEILLANCE; DRUG HAIR LEVEL; DRUG TREATMENT FAILURE; ECONOMIC ASPECT; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RESOURCE LIMITED SETTING; SECONDARY HEALTH CARE; TREATMENT DURATION;

ANTIRETROVIRAL DRUG RESISTANCE; RESOURCE-LIMITED SETTINGS; SECOND-LINE THERAPY;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEALTH RESOURCES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; MUTATION, MISSENSE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 84878333879     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit107     Document Type: Article

References (61)

1. World Health Organization. WHO HIV drug resistance report-2012. Geneva: World Health Organization, 2012.
2. UNAIDS. Global HIV/AIDS response: epidemic update and health sector progress towards universal access. Geneva: UNAIDS, 2011.
3. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: toward universal access. Recommendations for a public health approach. Geneva: World Health Organization, 2006.
4. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva: World Health Organization, 2010.
5. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(Suppl 2):1-13.
6. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-66.
7. Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis 2010; 201:1303-7.
8. Sow PS, Otieno LF, Bissagnene E, et al. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. J Acquir Immune Defic Syndr 2007; 44:262-7.
9. Hingankar NK, Thorat SR, Deshpande A, et al. Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. Clin Infect Dis 2012; 54(Suppl 4):S348-54.
10. Wadonda-Kabondo N, Hedt BL, van Oosterhout JJ, et al. A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi. Clin Infect Dis 2012; 54(Suppl 4):S355-61.
11. Wadonda-Kabondo N, Bennett D, van Oosterhout JJ, et al. Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program. Clin Infect Dis 2012; 54(Suppl 4):S362-8.
12. Vaz P, Augusto O, Bila D, et al. Surveillance of HIV drug resistance in children receiving antiretroviral therapy: a pilot study of the World Health Organization's generic protocol in Maputo, Mozambique. Clin Infect Dis 2012; 54(Suppl 4):S369-74.
13. Ugbena R, Aberle-Grasse J, Diallo K, et al. Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria. Clin Infect Dis 2012; 54(Suppl 4):S375-80.
14. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250-8.
15. Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660-9.
16. Hamers RL, Oyomopito R, Kityo C, et al. Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol 2012; 41:43-54.
17. Sunpath H, Wu B, Gordon M, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofo-vir-containing first-line regimen. AIDS 2012; 26:1679-84.
18. Tang MW, Kanki PJ, Shafer RW. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis 2012; 54:862-75.
19. Hosseinipour MC, van Oosterhout JJ, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line an-tiretroviral therapy. AIDS 2009; 23:1127-34.
20. Kumarasamy N, Madhavan V, Venkatesh KK, et al. High frequency of clinically significant mutations after first-line generic highly active anti-retroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis 2009; 49:306-9.
21. Reynolds SJ, Sendagire H, Newell K, et al. Virologic versus immunolog-ic monitoring and the rate of accumulated genotypic resistance to firstline antiretroviral drugs in Uganda. BMC Infect Dis 2012; 12:381.
22. Sigaloff KC, Ramatsebe T, Viana R, de Wit TF, Wallis CL, Stevens WS. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Ret-roviruses 2012; 28:171-5.
23. Ndembi N, Goodall RL, Dunn DT, et al. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus nevirapine and zido-vudine-lamivudine plus abacavir. J Infect Dis 2010; 201:106-13.
24. Gupta R, Pillay D, Ranopa M, et al. Rapid accumulation of thymidine-analog mutations and virologic implications in the absence of viral load monitoring. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 2011. http://retroconference.org/2011/ Abstracts/39986.htm
25. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 2009; 49:1928-35.
26. van Zyl GU, van der Merwe L, Claassen M, Zeier M, Preiser W. Antire-troviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. J Med Virol 2011; 83:1764-9.
27. Ngo-Giang-Huong N, Jourdain G, Amzal B, et al. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a Bayesian analysis. PLoS One 2011; 6:e27427.
28. Barth RE, Aitken SC, Tempelman H, et al. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther 2012; 17:377-86.
29. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-4.
30. Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, Hoepelman AI. Rapid accumulation of nonnucleoside reverse tran-scriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS 2008; 22:2210-12.
31. Coutsinos D, Invernizzi CF, Moisi D, et al. A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS One 2011; 6:e20208.
32. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wain-berg MA. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis 2009; 200:1202-6.
33. Tang M, Rhee S-Y, Bertagnolio S, et al. Nucleoside Reverse Transcrip-tase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications For Countries Phasing Out Stavudine. J Infect Dis 2013; 207(S2): S70-7.
34. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189: 837-46.
35. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 2012; 26:929-38.
36. Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010; 11:510-8.
37. van Zyl GU, van Mens TE, McIlleron H, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr 2011; 56:333-9.
38. Nijhuis M, van Maarseveen NM, Lastere S, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36.
39. Knops E, Brakier-Gingras L, Schulter E, Pfister H, Kaiser R, Verheyen J. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors. Med Microbiol Immunol 2012; 201:213-8.
40. Ghosn J, Delaugerre C, Flandre P, et al. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. PLoS One 2011; 6: e24798.
41. Larrouy L, Chazallon C, Landman R, et al. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients. Antimicrob Agents Chemo-ther 2010; 54:2910-9.
42. Fun A, Wensing AM, Verheyen J, Nijhuis M. Human immunodeficiency virus Gag and protease: partners in resistance. Retrovirology 2012; 9:63.
43. Knops E, Daumer M, Awerkiew S, et al. Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. J Antimi-crob Chemother 2010; 65:1472-6.
44. Sigaloff KC, Hamers RL, Wallis CL, et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis 2012; 205:1739-44.
45. Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monother-apy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009; 51:147-52.
46. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23:279-91.
47. Bartlett JA, Ribaudo HJ, Wallis CL, et al. Lopinavir/ritonavir mono-therapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS 2012; 26:1345-54.
48. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus te-nofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Antivir Ther 2012; 17:1351-61.
49. Luebbert J, Tweya H, Phiri S, et al. Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in lilongwe, Malawi. Clin Infect Dis 2012; 55:441-8.
50. Chung MH, Richardson BA, Tapia K, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med 2011; 8:e1000422.
51. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 2010; 376:1838-45.
52. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012; 156:817-33, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294.
53. Lorenzana SB, Hughes MD, Grinsztejn B, et al. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS 2012; 26:1083-93.
54. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Res Treat 2011; 2011:769627.
55. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 2010; 24:1679-87.
56. Saravanan S, Vidya M, Balakrishnan P, et al. Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India. Clin Infect Dis 2012; 54:995-1000.
57. Levison JH, Orrell C, Gallien S, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One 2012; 7:e32144.
58. Ferradini L, Ouk V, Segeral O, et al. High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc 2011; 14:14.
59. Maiga AI, Fofana DB, Cisse M, et al. Characterization of HIV-1 antire-troviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. J Antimicrob Chemother 2012; 67:2943-8.
60. Reynolds SJ, Laeyendecker O, Nakigozi G, et al. Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. AIDS Res Hum Retroviruses. BMC Infect Dis 2012; 12:381.
61. Hill A, McBride A, Sawyer A, et al. Resistance at Virological Failure Using Boosted Protease Inhibitors versus non Nucleoside Reverse Transcriptase Inhibitors as First Line Antiretroviral Therapy-Implications for Sustained Efficacy of ART in Resource Limited Settings. J Infect Dis 2013; 207(S2):S78-84.